Two-year tariff exemption offers temporary relief, but long-term implications could reshape India’s pharmaceutical exports
US President Donald Trump’s proposed tariff roadmap for imported generic medicines has sparked fresh concerns for India’s pharmaceutical industry, with experts warning that the policy could significantly alter global pharmaceutical supply chains over the coming years.
According to a News18 report, President Trump announced that imported generic medicines would remain exempt from tariffs for the next two years. However, he also indicated that companies manufacturing medicines outside the United States could eventually face tariffs of up to 100%, rising to 200% over time if production is not shifted to the US.
The announcement is part of a broader strategy aimed at strengthening domestic pharmaceutical manufacturing in the United States and reducing reliance on overseas production, particularly in the wake of supply chain vulnerabilities exposed during the COVID-19 pandemic.
India Faces Significant Exposure
India is widely recognised as the “pharmacy of the world” and remains one of the largest suppliers of affordable generic medicines globally. The United States is India’s largest pharmaceutical export destination, with Indian manufacturers supplying a substantial share of generic medicines used by American patients across therapeutic areas including diabetes, cardiovascular diseases, oncology and infectious diseases.
If the proposed tariffs are eventually implemented, Indian pharmaceutical exports could become significantly more expensive, potentially affecting the competitiveness of Indian manufacturers in one of their most important markets.
Two-Year Transition Period
The proposed two-year exemption provides pharmaceutical companies with an opportunity to reassess their manufacturing strategies before any new tariffs come into effect.
However, relocating pharmaceutical manufacturing is a complex process involving substantial capital investments, regulatory approvals, US FDA compliance, supply chain development and workforce expansion. Industry experts note that such transitions cannot be achieved as quickly as in many other manufacturing sectors.
Indian Pharma Companies May Need Strategic Realignment
Several leading Indian pharmaceutical companies—including Sun Pharma, Dr. Reddy’s Laboratories, Aurobindo Pharma, Lupin, Zydus Lifesciences, Cipla, Glenmark Pharmaceuticals and Torrent Pharmaceuticals—derive a significant portion of their revenues from the US market.
Companies with existing manufacturing facilities in the United States or diversified global production footprints may be better positioned to adapt to evolving trade policies. Smaller exporters, however, could face considerable financial and operational challenges should higher tariffs become a reality.
Commenting on the announcement, Thomas V. Abraham, Research Analyst at Mirae Asset Sharekhan, said, “We will await further clarity, but my initial view is that the proposed manufacturing requirement may not necessarily apply to all medicines, but rather to companies having manufacturing units in the US, similar to earlier policies for branded drugs. Most leading Indian pharmaceutical companies already have manufacturing facilities there, either organically or through acquisitions, and the proposed two-year transition period provides sufficient time to align with any new requirements. Additionally, during previous policy changes, branded drug companies were able to reach arrangements with the US government to mitigate the tax impact, and a similar approach could be explored by generic manufacturers. That said, investors are likely to remain cautious until there is greater clarity on the final tariff structure and implementation timeline.”
Potential Impact on Healthcare Costs
Generic medicines account for the vast majority of prescriptions filled in the United States because they offer affordable alternatives to branded medicines.
Should import costs increase substantially after the proposed transition period, manufacturers may pass on some of the additional costs through the healthcare supply chain. This could increase expenditure for insurers, healthcare providers and, ultimately, patients while also affecting medicine availability if some manufacturers reduce exports.
Policy Yet to Be Finalised
While the announcement has generated widespread attention across global pharmaceutical markets, the proposal has not yet completed the formal US policy-making process. The final tariff structure, implementation timeline and potential exemptions will depend on future regulatory decisions and bilateral trade negotiations.
As reported by News18, pharmaceutical trade is expected to feature prominently in future India-US discussions, with India likely to seek exemptions for essential medicines, longer transition timelines and sector-specific arrangements.
Outlook
Although the proposed two-year exemption provides immediate relief, the announcement signals a potential long-term shift in the global pharmaceutical landscape.
For India’s pharmaceutical industry, the coming years could prove critical in determining manufacturing strategies, investment priorities and export competitiveness. While larger companies with international manufacturing capabilities may be able to adapt more readily, smaller exporters could face increasing pressure if the proposed tariff regime is implemented.
The proposal should be viewed not as an immediate disruption, but as an early indication that pharmaceutical manufacturing could increasingly move closer to the US market in the years ahead.
